Kymera Therapeutics Inc $KYMR

Recent News (5)

• Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock Investing.com · 04 Sep 2026 Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock
• Kymera Therapeutics to Participate in Upcoming September Investor Conferences GlobeNewswire · 02 Sep 2026 WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medici…
• Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses GlobeNewswire · 01 Sep 2026 Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027
• Oppenheimer raises Kymera Therapeutics price target on trial timing Investing.com · 05 Aug 2026 Oppenheimer raises Kymera Therapeutics price target on trial timing
• Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer GlobeNewswire · 27 Jul 2026 Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio